Discovers precision medicines by targeting molecular machines that drive human diseases, using a proprietary platform to identify and validate novel therapeutic targets. This approach addresses the limitations of traditional drug discovery by enabling the development of treatments tailored to the underlying biological mechanisms of various conditions.
Funding
$236M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional drug discovery methods often struggle to identify and validate effective therapeutic targets, particularly for diseases driven by highly dynamic proteins. This limitation hinders the development of precision medicines tailored to the underlying biological mechanisms of various conditions.
Solution
MOMA Therapeutics is developing precision medicines by targeting molecular machines, which are highly dynamic proteins that drive human diseases. The company utilizes a proprietary platform to identify and validate novel therapeutic targets that have been previously inaccessible. This approach enables the development of treatments specifically designed to address the root causes of diseases at the molecular level. By focusing on these dynamic proteins, MOMA aims to create more effective and targeted therapies for a range of conditions.
Target Audience
The primary target audience includes patients suffering from diseases driven by dysregulation of molecular machines, and pharmaceutical companies seeking innovative drug targets.
Features
- Proprietary platform for identifying and validating novel therapeutic targets
- Focus on molecular machines (highly dynamic proteins)
- Development of precision medicines tailored to specific disease mechanisms